Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-16 23:56 | 2025-06-12 | ETON | Eton Pharmaceuticals, Inc. | Krempa David | Officer | SELL | $14.83 | 34,000 | $504,319 | 612,646 |
| 2025-06-16 23:03 | 2025-06-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $14.60 | 11,366 | $165,931 | 101,651 |
| 2025-06-16 23:48 | 2025-06-12 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Officer | OPT+S | $32.23 | 97,483 | $3,141,877 | 99,713 |
| 2025-06-16 23:42 | 2025-06-13 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer | SELL | $10.03 | 127,905 | $1,283,194 | 364,927 |
| 2025-06-17 01:05 | 2025-06-13 | TERN | Terns Pharmaceuticals, Inc. | Gengos Andrew | Officer | BUY | $3.81 | 15,000 | $57,083 | 15,000 |
| 2025-06-16 22:40 | 2025-05-28 | ANTX | AN2 Therapeutics, Inc. | Leonard Braden Michael | 10% owner | SELL | $1.09 | 200,000 | $218,000 | 3,017,432 |
| 2025-06-17 04:10 | 2025-06-13 | VNDA | Vanda Pharmaceuticals Inc. | Mitchell Stephen Ray | Director | SELL | $4.59 | 7,000 | $32,130 | 97,082 |
| 2025-06-17 02:31 | 2025-06-16 | XNCR | Xencor Inc | GUSTAFSON KURT A | Director | SELL | $9.22 | 2,993 | $27,595 | 20,183 |
| 2025-06-17 02:26 | 2025-06-16 | XNCR | Xencor Inc | Feigal Ellen | Director | SELL | $9.22 | 2,993 | $27,595 | 19,183 |
| 2025-06-17 03:06 | 2025-06-12 | TYRA | Tyra Biosciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $10.19 | 163,287 | $1,664,695 | 10,259,291 |
| 2025-06-17 02:35 | 2025-06-16 | XNCR | Xencor Inc | Montgomery Alan Bruce | Director | SELL | $9.22 | 2,215 | $20,422 | 20,611 |
| 2025-06-17 00:00 | 2025-06-13 | IMUX | IMMUNIC, INC. | Nash Duane | Director, Officer | BUY | $0.83 | 20,000 | $16,694 | 36,032 |
| 2025-06-17 02:05 | 2025-06-12 | TYRA | Tyra Biosciences, Inc. | KAPLAN GILLA | Director | SELL | $10.32 | 51,814 | $534,565 | 37,809 |
| 2025-06-17 02:22 | 2025-06-16 | XNCR | Xencor Inc | RANIERI RICHARD J | Director | SELL | $9.22 | 2,993 | $27,595 | 19,183 |
| 2025-06-17 02:30 | 2025-06-16 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Director | SELL | $9.22 | 3,173 | $29,255 | 18,905 |
| 2025-06-17 01:01 | 2025-06-13 | OGEN | ORAGENICS INC | Odyssey Health, Inc. | 10% owner | SELL | $4.36 | 10,000 | $43,600 | 7,044 |
| 2025-06-16 17:22 | 2025-06-13 | ACUT | Accustem Sciences Inc. | CERRONE GABRIELE M | Director, 10% owner | BUY | $1.02 | 2,400 | $2,440 | 6,502,400 |
| 2025-06-16 15:48 | 2025-06-12 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $279.96 | 11,000 | $3,079,514 | 36,781 |
| 2025-06-17 00:19 | 2025-06-16 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $33.80 | 5,000 | $169,000 | 403,108 |
| 2025-06-17 00:24 | 2025-06-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $61.37 | 400 | $24,548 | 79,345 |
| 2025-06-17 00:47 | 2025-06-13 | TGTX | TG THERAPEUTICS, INC. | Echelard Yann | Director | SELL | $36.94 | 10,000 | $369,400 | 228,816 |
| 2025-06-14 02:50 | 2025-06-13 | LTRN | Lantern Pharma Inc. | Kreis Leslie W. | 10% owner | SELL | $3.09 | 40,000 | $123,600 | 114,272 |
| 2025-06-13 13:01 | 2025-06-10 | LTRN | Lantern Pharma Inc. | Kreis Leslie W. | 10% owner | SELL | $3.38 | 61,613 | $208,270 | 118,626 |
| 2025-06-13 23:18 | 2025-06-11 | MIRM | Mirum Pharmaceuticals, Inc. | Fairey William | Director | SELL | $48.42 | 3,203 | $155,091 | 2,500 |
| 2025-06-14 02:57 | 2025-06-13 | LTRN | Lantern Pharma Inc. | Fletcher Aaron G.L. | 10% owner | SELL | $3.09 | 40,000 | $123,600 | 114,272 |
| 2025-06-13 13:06 | 2025-06-10 | LTRN | Lantern Pharma Inc. | Fletcher Aaron G.L. | 10% owner | SELL | $3.38 | 61,613 | $208,270 | 118,626 |
| 2025-06-14 02:38 | 2025-06-12 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | Officer | SELL | $10.00 | 300 | $3,000 | 101,817 |
| 2025-06-14 03:00 | 2025-06-13 | WVE | Wave Life Sciences Ltd. | Verdine Gregory L. | Director | SELL | $6.95 | 30,000 | $208,500 | 282,517 |
| 2025-06-14 00:05 | 2025-06-11 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $1.85 | 5,000 | $9,250 | 28,323 |
| 2025-06-13 15:00 | 2025-06-12 | SLS | SELLAS Life Sciences Group, Inc. | VAN NOSTRAND ROBERT L | Director | BUY | $1.48 | 10,000 | $14,800 | 20,400 |
| 2025-06-13 17:26 | 2025-06-11 | ACUT | Accustem Sciences Inc. | CERRONE GABRIELE M | Director, 10% owner | BUY | $0.50 | 37,196 | $18,464 | 6,500,000 |
| 2025-06-14 02:00 | 2025-06-11 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Director | SELL | $7.03 | 10,712 | $75,348 | 66,377 |
| 2025-06-13 00:51 | 2025-06-10 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer | SELL | $114.54 | 500 | $57,271 | 32,403 |
| 2025-06-13 01:34 | 2025-06-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Director, Officer | SELL | $54.05 | 37,837 | $2,044,939 | 556,487 |
| 2025-06-13 01:33 | 2025-06-10 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Officer | SELL | $54.00 | 2,358 | $127,323 | 167,363 |
| 2025-06-13 01:33 | 2025-06-10 | AKRO | Akero Therapeutics, Inc. | White William Richard | Officer | SELL | $54.00 | 2,804 | $151,402 | 59,155 |
| 2025-06-13 01:33 | 2025-06-10 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Officer | SELL | $54.00 | 2,803 | $151,351 | 92,231 |
| 2025-06-13 01:32 | 2025-06-10 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | Officer | SELL | $54.00 | 919 | $49,625 | 32,573 |
| 2025-06-13 01:32 | 2025-06-10 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | Officer | SELL | $53.99 | 2,493 | $134,605 | 198,047 |
| 2025-06-12 23:19 | 2025-06-10 | AMRX | Amneal Pharmaceuticals Inc. | Patel Gautam | Director | SELL | $8.02 | 56,426 | $452,537 | 1,704,050 |
| 2025-06-13 00:51 | 2025-06-11 | ONC | BeOne Medicines Ltd. | Ball Titus B. | Officer | SELL | $258.36 | 134 | $34,620 | 0 |
| 2025-06-13 00:39 | 2025-06-10 | ONC | BeOne Medicines Ltd. | Wang Xiaodong | Director | OPT+S | $262.82 | 41,760 | $10,975,317 | 0 |
| 2025-06-13 01:18 | 2025-06-11 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Officer | OPT+S | $32.88 | 20,000 | $657,694 | 80,195 |
| 2025-06-12 23:32 | 2025-06-10 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% owner | BUY | $15.82 | 7,930 | $125,484 | 85,000 |
| 2025-06-13 03:17 | 2025-06-10 | BHC | Bausch Health Companies Inc. | Paulson John | Director | BUY | $5.27 | 2,788,608 | $14,700,147 | 29,227,643 |
| 2025-06-13 00:00 | 2025-06-10 | CPRX | CATALYST PHARMACEUTICALS, INC. | Sundaram Preethi | Officer | SELL | $26.41 | 3,924 | $103,649 | 41,081 |
| 2025-06-12 23:50 | 2025-06-10 | RYTM | RHYTHM PHARMACEUTICALS, INC. | German Christopher Paul | Officer | OPT+S | $67.19 | 2,069 | $139,016 | 1,889 |
| 2025-06-12 23:21 | 2025-06-10 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | OPT+S | $91.16 | 45,163 | $4,117,068 | 83,111 |
| 2025-06-12 23:20 | 2025-06-10 | INSM | INSMED Inc | Schaeffer Orlov S Nicole | Officer | OPT+S | $92.09 | 137,472 | $12,659,260 | 89,407 |
| 2025-06-12 23:19 | 2025-06-10 | INSM | INSMED Inc | Bonstein Sara | Officer | OPT+S | $89.12 | 57,766 | $5,148,025 | 103,412 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.